4 drugs in shortage

Here are four new drug shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists. 

1. Gemcitabine hydrochloride injection: Hospira has discontinued manufacturing of its 200 milligram/5.26 milliliter, 1 gram/26.3 milliliter and 2 gram/52.6 milliliter NovaPlus single-dose glass vials of gemcitabine hydrochloride injection, an oncology medication used to treat various cancers.
2. Ibandronate sodium injection: Apotex and Eugia US have reported a shortage of Ibandronate sodium 1 milligram/milliliter and 3 milliliter prefilled syringes, an intravenous drug used to treat osteoporosis. No reason was provided and supply is intermittent with Apotex estimating resupply by mid-November.
3. Metyrosine capsules (Demser): Bausch Health has reported a shortage of its 250 milligram Demser oral capsules, used to manage pheochromocytoma. No reason was provided and the company cannot estimate a resupply date. Alternative 250 milligram capsules from Amneal pharmaceuticals are available, and capsules from Dr. Reddy’s Laboratories are forthcoming.
4. Mometasone furoate and formoterol fumarate inhalation aerosol (Dulera): Organon has reported a shortage of its 100 microgram/5 microgram and 13 gram, and  100 microgram/5 microgram and 8.8 gram metered-dose inhalers of Dulera, used to manage asthma and obstructive pulmonary disease. No reason for the shortage was provided. Limited supply of alternative strengths including 50 microgram/5 microgram and 200 microgram/5 microgram is available, with the 100 microgram/5 microgram 8.8 gram inhalers expected to be resupplied by mid-October and 13 gram inhalers by mid-September.

The post 4 drugs in shortage appeared first on Becker’s Hospital Review | Healthcare News & Analysis.